Sirtuin modulating compounds
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
1. A compound of the formula:
or a salt thereof, wherein:
each of R 23 and R 24 is independently selected from H, —CH 3 and a solubilizing group;
R 25 is selected from H and a solubilizing group; and
R 19 is:
wherein:
each Z 10 , Z 11 , Z 12 and Z 13 is independently selected from CR 20 and CR 1 ″;
wherein:
zero to one R 20 is a solubilizing group; and
zero to one R 1 ″ is an optionally substituted C 1 -C 3 straight or branched alkyl;
each R 20 is independently selected from H and a solubilizing group;
R 21 is selected from —NR 1 ′—C(O)— and —C(O)—NR 1 ′; and
each R 1 ′ is independently selected from H and optionally substituted C 1 -C 3 straight or branched alkyl, wherein when R 1 ′ and/or R 1 ″ is substituted, R 1 ′ and/or R 1 ″ is substituted with one or more of —OH, halogen, —OR a , —O—COR a , —COR a , —C(O)R a , —CN, —NO 2 , —COOH, —COOR a , —OCO 2 R a , —C(O)NR a R b , —OC(O)NR a R b , —SO 3 H, —NH 2 , —NHR a , —N(R a R b ), —COOR a , —CHO, —CONH 2 , —CONHR a , —CON(R a R b ), —NHCOR a , —NRCOR a , —NHCONH 2 , —NHCONR a H, —NHCON(R a R b ), —NR c CONH 2 , —NR c CONR a H, —NR c CON(R a R b ), —C(═NH)—NH 2 , —C(═NH)—NHR a , —C(═NH)—N(R a R b ), —C(═NR c )—NH 2 , —C(═NR c )—NHR a , —C(═NR c )—N(R a R b ), —NH—C(═NH)—NHR a , —NH—C(═NH)—N(R a R b ), —NH—C(═NR c )—NH 2 , —NH—C(═NR c )—NHR a , —NH—C(═NR c )—N(R a R b ), —NR d —C(═NH)—NH 2 , —NR d —C(═NH)—NHR a , —NR d —C(═NH)—N(R a R b ), —NR d —C(═NR c )—NH 2 , —NR d —C(═NR c )—NHR a , —NR d —C(═NR c )—N(R a R b ), —NHNH 2 , —NHNHR a , —SO 2 NH 2 , —SO 2 NHR a , —SO 2 NR a R b , —CH═CHR a , —CH═CR a R b , —CR c ═CR a R b , CR c ═CHR a , —CR c ═CR a R b , —CCR a , —SH, —SO k R a , —S(O) k OR a and —NH—C(═NH)—NH 2 , wherein
k is 0, 1 or 2;
R a -R d are each independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group; and
—NR a R b , taken together, can also form a substituted or unsubstituted non-aromatic heterocyclic group;
wherein a non-aromatic heterocyclic group, benzylic group or aryl group can also have an aliphatic or substituted aliphatic group as a substituent; a substituted aliphatic group can also have a non-aromatic heterocyclic ring, a substituted non-aromatic heterocyclic ring, benzyl, substituted benzyl, aryl or substituted aryl group as a substituent; and a substituted aliphatic, non-aromatic heterocyclic group, substituted aryl, or substituted benzyl group can have more than one substituent; and
R 31 is selected from an optionally substituted monocyclic or bicyclic aryl, and an optionally substituted monocyclic or bicyclic heteroaryl, with the proviso that R 31 is not 2,4-dimethoxyphenyl.
2. A composition comprising a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein:
each of R 23 and R 24 is independently selected from H, —CH 3 and a solubilizing group;
R 25 is selected from H and a solubilizing group; and
R 19 is:
wherein:
each Z 10 , Z 11 , Z 12 and Z 13 is independently selected from CR 20 and CR 1 ″;
wherein:
zero to one R 20 is a solubilizing group; and
zero to one R 1 ″ is an optionally substituted C 1 -C 3 straight or branched alkyl;
each R 20 is independently selected from H and a solubilizing group;
R 21 is selected from —NR 1 ′—C(O)—and —C(O)—NR 1 ′; and
each R 1 ′ is independently selected from H and optionally substituted C 1 -C 3 straight or branched alkyl, wherein when R 1 ′ and/or R 1 ″ is substituted, R 1 ′ and/or R 1 ″ is substituted with one or more of —OH, halogen, —OR a , —O—COR a , —COR a , —C(O)R a , —CN, —NO 2 , —COOH, —COOR a , —OCO 2 R a , —C(O)NR a R b , —OC(O)NR a R b , —SO 3 H, —NH 2 , —NHR a , —N(R a R b ), —COOR a , —CHO, —CONH 2 , —CONHR a , —CON(R a R b ), —NHCOR a , —NRCOR a , —NHCONH 2 , —NHCONR a H, —NHCON(R a R b ), —NR c CONH 2 , —NR c CONR a H, —NR c CON(R a R b ), —C(═NH)—NH 2 , —C(═NH)—NHR a , —C(═NH)—N(R a R b ), —C(═NR c )—NH 2 , —C(═NR c )—NHR a , —C(═NR c )—N(R a R b ), —NH—C(═NH)—NHR a , —NH—C(═NH)—N(R a R b ), —NH—C(═NR c )—NH 2 , —NH—C(═NR c )—NHR a , —NH—C(═NR c )—N(R a R b ), —NR d —C(═NH)—NH 2 , —NR d —C(═NH)—NHR a , —NR d —C(═NH)—N(R a R b ), —NR d —C(═NR c )—NH 2 , —NR d —C(═NR c )—NHR a , —NR d —C(═NR c )—N(R a R b ), —NHNH 2 , —NHNHR a , —SO 2 NH 2 , —SO 2 NHR a , —SO 2 NR a R b , —CH═CHR a , —CH═CR a R b , —CR c ═CR a R b , CR c ═CHR a , —CR c ═CR a R b , —CCR a , —SH, —SO k R a , —S(O) k OR a and —NH—C(═NH)—NH 2 , wherein
k is 0, 1 or 2;
R a -R d are each independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group; and
—NR a R b , taken together, can also form a substituted or unsubstituted non-aromatic heterocyclic group;
wherein a non-aromatic heterocyclic group, benzylic group or aryl group can also have an aliphatic or substituted aliphatic group as a substituent; a substituted aliphatic group can also have a non-aromatic heterocyclic ring, a substituted non-aromatic heterocyclic ring, benzyl, substituted benzyl, aryl or substituted aryl group as a substituent; and a substituted aliphatic, non-aromatic heterocyclic group, substituted aryl, or substituted benzyl group can have more than one substituent; and
R 31 is selected from an optionally substituted monocyclic or bicyclic aryl and an optionally substituted monocyclic or bicyclic heteroaryl, wherein the composition is pyrogen-free.
3. A pharmaceutical composition comprising:
a) a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein:
each of R 23 and R 24 is independently selected from H, —CH 3 and a solubilizing group;
R 25 is selected from H and a solubilizing group; and
R 19 is:
wherein:
each Z 10 , Z 11 , Z 12 and Z 13 is independently selected from CR 20 and CR 1 ″;
wherein:
zero to one R 20 is a solubilizing group; and
zero to one R 1 ″ is an optionally substituted C 1 -C 3 straight or branched alkyl;
each R 20 is independently selected from H and a solubilizing group;
R 21 is selected from —NR 1 ′—C(O)—and —C(O)—NR 1 ′; and
each R 1 ′ is independently selected from H and optionally substituted C 1 -C 3 straight or branched alkyl, wherein when R 1 ′ and/or R 1 ″ is substituted, R 1 ′ and/or R 1 ″ is substituted with one or more of —OH, halogen, —OR a , —O—COR a , —COR a , —C(O)R a , —CN, —NO 2 , —COOH, —COOR a , —OCO 2 R a , —C(O)NR a R b , —OC(O)NR a R b , —SO 3 H, —NH 2 , —NHR a , —N(R a R b ), —COOR a , —CHO, —CONH 2 , —CONHR a , —CON(R a R b ), —NHCOR a , —NRCOR a , —NHCONH 2 , —NHCONR a H, —NHCON(R a R b ), —NR c CONH 2 , —NR c CONR a H, —NR c CON(R a R b ), —C(═NH)—NH 2 , —C(═NH)—NHR a , —C(═NH)—N(R a R b ), —C(═NR c )—NH 2 , —C(═NR c )—NHR a , —C(═NR c )—N(R a R b ), —NH—C(═NH)—NHR a , —NH—C(═NH)—N(R a R b ), —NH—C(═NR c )—NH 2 , —NH—C(═NR c )—NHR a , —NH—C(═NR c )—N(R a R b ), —NR d —C(═NH)—NH 2 , —NR d —C(═NH)—NHR a , —NR d —C(═NH)—N(R a R b ), —NR d —C(═NR c )—NH 2 , —NR d —C(═NR c )—NHR a , —NR d —C(═NR c )—N(R a R b ), —NHNH 2 , —NHNHR a , —SO 2 NH 2 , —SO 2 NHR a , —SO 2 NR a R b , —CH═CHR a , —CH═CR a R b , —CR c ═CR a R b , CR c ═CHR a , —CR c ═CR a R b , —CCR a , —SH, —SO k R a , —S(O) k OR a and —NH—C(═NH)—NH 2 , wherein
k is 0, 1 or 2;
R a -R d are each independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group; and
—NR a R b , taken together, can also form a substituted or unsubstituted non-aromatic heterocyclic group;
wherein a non-aromatic heterocyclic group, benzylic group or aryl group can also have an aliphatic or substituted aliphatic group as a substituent; a substituted aliphatic group can also have a non-aromatic heterocyclic ring, a substituted non-aromatic heterocyclic ring, benzyl, substituted benzyl, aryl or substituted aryl group as a substituent; and a substituted aliphatic, non-aromatic heterocyclic group, substituted aryl, or substituted benzyl group can have more than one substituent; and
R 31 is selected from an optionally substituted monocyclic or bicyclic aryl and an optionally substituted monocyclic or bicyclic heteroaryl,
b) a pharmaceutically acceptable carrier or diluent.
4. A packaged pharmaceutical comprising a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein:
each of R 23 and R 24 is independently selected from H, —CH 3 and a solubilizing group;
R 25 is selected from H and a solubilizing group; and
R 19 is:
wherein:
each Z 10 , Z 11 , Z 12 and Z 13 is independently selected from CR 20 and CR 1 ″;
wherein:
zero to one R 20 is a solubilizing group; and
zero to one R 1 ″ is an optionally substituted C 1 -C 3 straight or branched alkyl;
each R 20 is independently selected from H and a solubilizing group;
R 21 is selected from —NR 1 ′—C(O)—and —C(O)—NR 1 ′, and
each R 1 ′ is independently selected from H and optionally substituted C 1 -C 3 straight or branched alkyl, wherein when R 1 ′ and/or R 1 ″ is substituted, R 1 ′ and/or R 1 ″ is substituted with one or more of —OH, halogen, —OR a , —O—COR a , —COR a , —C(O)R a , —CN, —NO 2 , —COOH, —COOR a , —OCO 2 R a , —C(O)NR a R b , —OC(O)NR a R b , —SO 3 H, —NH 2 , —NHR a , —N(R a R b ), —COOR a , —CHO, —CONH 2 , —CONHR a , —CON(R a R b ), —NHCOR a , —NRCOR a , —NHCONH 2 , —NHCONR a H, —NHCON(R a R b ), —NR c CONH 2 , —NR c CONR a H, —NR c CON(R a R b ), —C(═NH)—NH 2 , —C(═NH)—NHR a , —C(═NH)—N(R a R b ), —C(═NR c )—NH 2 , —C(═NR c )—NHR a , —C(═NR c )—N(R a R b ), —NH—C(═NH)—NHR a , —NH—C(═NH)—N(R a R b ), —NH—C(═NR c )—NH 2 , —NH—C(═NR c )—NHR a , —NH—C(═NR c )—N(R a R b ), —NR d —C(═NH)—NH 2 , —NR d —C(═NH)—NHR a , —NR d —C(═NH)—N(R a R b ), —NR d —C(═NR c )—NH 2 , —NR d —C(═NR c )—NHR a , —NR d —C(═NR c )—N(R a R b ), —NHNH 2 , —NHNHR a , —SO 2 NH 2 , —SO 2 NHR a , —SO 2 NR a R b , —CH═CHR a , —CH═CR a R b , —CR c ═CR a R b , CR c ═CHR a , —CR c ═CR a R b , —CCR a , —SH, —SO k R a , —S(O) k OR a and —NH—C(═NH)-NH 2 wherein
k is 0, 1 or 2;
R a -R d are each independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group; and
—NR a R b , taken together, can also form a substituted or unsubstituted non-aromatic heterocyclic group;
wherein a non-aromatic heterocyclic group, benzylic group or aryl group can also have an aliphatic or substituted aliphatic group as a substituent; a substituted aliphatic group can also have a non-aromatic heterocyclic ring, a substituted non-aromatic heterocyclic ring, benzyl, substituted benzyl, aryl or substituted aryl group as a substituent; and a substituted aliphatic, non-aromatic heterocyclic group, substituted aryl, or substituted benzyl group can have more than one substituent; and
R 31 is selected from an optionally substituted monocyclic or bicyclic aryl and an optionally substituted monocyclic or bicyclic heteroaryl,
and instructions for using the compound to modulate a sirtuin.
5. The compound according to claim 1 , wherein R 25 is selected from H, —CH 2 —N(CH 3 ) 2 and
6. The compound according to claim 1 , wherein R 23 and R 24 are H.
7. The compound according to claim 1 , wherein R 19 is substituted with:
a) up to three —O—CH 3 groups; or
b) one —N(CH 3 ) 2 group.
8. The compound according to claim 1 , wherein R 21 is —NH—C( 0 )—.